(Q33603520)

28 July 2017

1 reference

title

Treatment of cancer of the exocrine pancreas (English)

1 reference

28 July 2017

0 references

Huguier M

1

1 reference

PubMed ID

10219866

28 July 2017

Mason NP

series ordinal

2

1 reference

PubMed ID

10219866

28 July 2017

language of work or name

English

0 references

publication date

1 March 1999

1 reference

The American Journal of Surgery

28 July 2017

1 reference

28 July 2017

177

1 reference

28 July 2017

3

1 reference

28 July 2017

257-265

1 reference

Morbidity and mortality after radical and palliative pancreatic cancer surgery. Risk factors influencing the short-term results

28 July 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2899%2900003-3

Results of resection for cancer of the exocrine pancreas: a study from the French Association of Surgery

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2899%2900003-3

Pancreatic or liver resection for malignancy is safe and effective for the elderly

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2899%2900003-3

Economics of pancreatoduodenectomy in the elderly

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2899%2900003-3

Results of surgical palliation for cancer of the head of the pancreas and periampullary region

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2899%2900003-3

Carcinoma of the pancreatic head and periampullary region. Tumor staging with laparoscopy and laparoscopic ultrasonography

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2899%2900003-3

The value of minimal access surgery in the staging of patients with potentially resectable peripancreatic malignancy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2899%2900003-3

Prospective controlled trial of transhepatic biliary endoprosthesis versus bypass surgery for incurable carcinoma of head of pancreas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2899%2900003-3

Endoscopic biliary endoprosthesis in the palliation of malignant obstruction of the distal common bile duct: a randomized trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2899%2900003-3

Randomised trial of endoscopic endoprosthesis versus operative bypass in malignant obstructive jaundice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2899%2900003-3

Randomised trial of endoscopic stenting versus surgical bypass in malignant low bileduct obstruction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2899%2900003-3

Guidelines for the application of surgery and endoprostheses in the palliation of obstructive jaundice in advanced cancer of the pancreas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2899%2900003-3

Prognostic indicators for survival after resection of pancreatic adenocarcinoma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2899%2900003-3

Treatment and survival in 13560 patients with pancreatic cancer, and incidence of the disease, in the West Midlands: An epidemiological study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2899%2900003-3

The National Cancer Data Base report on pancreatic cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2899%2900003-3

Long-term survival after curative resection for pancreatic ductal adenocarcinoma. Clinicopathologic analysis of 5-year survivors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2899%2900003-3

Significance of lymph node metastases in patients with pancreatic cancer undergoing curative resection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2899%2900003-3

Survival after resection for ductal adenocarcinoma of the pancreas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2899%2900003-3

Carcinoma of the pancreas and periampullary region: palliation versus cure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2899%2900003-3

Pancreaticoduodenectomy. Does it have a role in the palliation of pancreatic cancer?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2899%2900003-3

Palliative operations for pancreatic carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2899%2900003-3

A prospective, randomized clinical investigation of cholecystoenterostomy and choledochoenterostomy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2899%2900003-3

Palliative operations for pancreatic cancer in the hospitals of the U.S. Department of Veterans Affairs from 1987 to 1991.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2899%2900003-3

Delayed gastric emptying after palliative gastrojejunostomy for carcinoma of the pancreas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2899%2900003-3

Chemical splanchnicectomy in patients with unresectable pancreatic cancer. A prospective randomized trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2899%2900003-3

Surgical palliation for pancreatic cancer. The UCLA experience

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2899%2900003-3

The Effects of Regionalization on Cost and Outcome for One General High-Risk Surgical Procedure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2899%2900003-3

Relation of perioperative deaths to hospital volume among patients undergoing pancreatic resection for malignancy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2899%2900003-3

National patterns of care for pancreatic cancer. Results of a survey by the Commission on Cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2899%2900003-3

Low mortality following resection for pancreatic and periampullary tumours in 1026 patients: UK survey of specialist pancreatic units. UK Pancreatic Cancer Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2899%2900003-3

Tumor size is the primary prognosticator for pancreatic cancer after regional pancreatectomy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2899%2900003-3

Population-based analysis of treatment of pancreatic cancer and Whipple resection: Department of Defense hospitals, 1989-1994

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2899%2900003-3

Survival after pancreatoduodenectomy. 118 consecutive resections without an operative mortality

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2899%2900003-3

Standards for pancreatic resection in the 1990s

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2899%2900003-3

Prognostic factors after resection of ampullary carcinoma: multivariate survival analysis in comparison with ductal cancer of the pancreatic head

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2899%2900003-3

Pancreaticoduodenectomy for pancreatic adenocarcinoma: postoperative adjuvant chemoradiation improves survival. A prospective, single-institution experience.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2899%2900003-3

Complications following pancreaticoduodenectomy. Current management

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2899%2900003-3

Role of octreotide in the prevention of postoperative complications following pancreatic resection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2899%2900003-3

Efficacy of octreotide in the prevention of pancreatic fistula after elective pancreatic resections: a prospective, controlled, randomized clinical trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2899%2900003-3

Optimal management of the pancreatic remnant after pancreaticoduodenectomy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2899%2900003-3

Prospective, randomized trial of octreotide to prevent pancreatic fistula after pancreaticoduodenectomy for malignant disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2899%2900003-3

Current experience with pancreatogastrostomy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2899%2900003-3

A prospective randomized trial of pancreaticogastrostomy versus pancreaticojejunostomy after pancreaticoduodenectomy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2899%2900003-3

Erythromycin accelerates gastric emptying after pancreaticoduodenectomy. A prospective, randomized, placebo-controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2899%2900003-3

The advantages of pylorus-preserving pancreatoduodenectomy in malignant disease of the pancreas and periampullary region

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2899%2900003-3

Pylorus-preserving versus standard pancreatico-duodenectomy: an analysis of 110 pancreatic and periampullary carcinomas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2899%2900003-3

Comparison between pylorus-preserving and Whipple pancreatoduodenectomy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2899%2900003-3

Pylorus-preserving Whipple resection for pancreatic cancer. Is it any better?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2899%2900003-3

Lymph node metastases in carcinoma of the head of the pancreas region

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2899%2900003-3

Pylorus-preserving pancreatoduodenectomy. Is it an adequate cancer operation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2899%2900003-3

Total pancreatectomy for ductal cell carcinoma of the pancreas. An update

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2899%2900003-3

Total pancreatectomy for ductal adenocarcinoma of the pancreas with special reference to resection of the portal vein and multicentric cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2899%2900003-3

Metabolic consequences of (regional) total pancreatectomy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2899%2900003-3

A reappraisal of total pancreatectomy for pancreatic cancer: results from U.S. Veterans Affairs hospitals, 1987-1991.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2899%2900003-3

Improved glucose metabolism after subtotal pancreatectomy for pancreatic cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2899%2900003-3

Clinical significance of portal invasion by pancreatic head carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2899%2900003-3

Rationale for en bloc vein resection in the treatment of pancreatic adenocarcinoma adherent to the superior mesenteric-portal vein confluence. Pancreatic Tumor Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2899%2900003-3

Isolated portal vein involvement in pancreatic adenocarcinoma. A contraindication for resection?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2899%2900003-3

Carcinoma of the periampullary region: who benefits from portal vein resection?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2899%2900003-3

Preoperative indications for extended pancreatectomy for locally advanced pancreas cancer involving the portal vein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2899%2900003-3

Practical grouping of positive lymph nodes in pancreatic head cancer treated by an extended pancreatectomy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2899%2900003-3

Assessment of disseminated pancreatic cancer: a comparison of traditional exploratory laparotomy and radioimmunoguided surgery

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2899%2900003-3

Surgery for left-sided pancreatic cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2899%2900003-3

Carcinoma of the body and tail of the pancreas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2899%2900003-3

Management of adenocarcinoma of the body and tail of the pancreas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2899%2900003-3

A phase III trial on the therapy of advanced pancreatic carcinoma. Evaluations of the Mallinson regimen and combined 5-fluorouracil, doxorubicin, and cisplatin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2899%2900003-3

Randomised trial of epirubicin alone versus 5-fluorouracil, epirubicin and mitomycin C in locally advanced and metastatic carcinoma of the pancreas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2899%2900003-3

A phase III comparison trial of streptozotocin, mitomycin, and 5-fluorouracil with cisplatin, cytosine arabinoside, and caffeine in patients with advanced pancreatic carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2899%2900003-3

Chemotherapy prolongs survival in inoperable pancreatic carcinoma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2899%2900003-3

Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2899%2900003-3

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2899%2900003-3

Adjuvant combination chemotherapy (AMF) following radical resection of carcinoma of the pancreas and papilla of Vater--results of a controlled, prospective, randomised multicentre study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2899%2900003-3

Treatment of locally unresectable cancer of the stomach and pancreas: a randomized comparison of 5-fluorouracil alone with radiation plus concurrent and maintenance 5-fluorouracil--an Eastern Cooperative Oncology Group study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2899%2900003-3

Radiation therapy combined with Adriamycin or 5-fluorouracil for the treatment of locally unresectable pancreatic carcinoma. Gastrointestinal Tumor Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2899%2900003-3

Evaluation of external-beam radiation therapy plus 5-fluorouracil (5-FU) versus external-beam radiation therapy plus hycanthone (HYC) in confined, unresectable pancreatic cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2899%2900003-3

Further evidence of effective adjuvant combined radiation and chemotherapy following curative resection of pancreatic cancer. Gastrointestinal Tumor Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2899%2900003-3

Intraoperative electron beam radiation therapy (IOEBRT) for carcinoma of the exocrine pancreas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2899%2900003-3

Intraoperative radiotherapy for pancreatic carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2899%2900003-3

Intraoperative radiation therapy following pancreaticoduodenectomy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2899%2900003-3

Intraoperative radiation therapy adjuvant to resection in the treatment of pancreatic cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2899%2900003-3

Preoperative chemoradiation, pancreaticoduodenectomy, and intraoperative radiation therapy for adenocarcinoma of the pancreatic head

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2899%2900003-3

Treatment of adenocarcinoma of the pancreas with somatostatin and gonadoliberin (luteinizing hormone-releasing hormone). The French Associations for Surgical Research

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2899%2900003-3

A prospective randomised controlled trial of tamoxifen and cyproterone acetate in pancreatic carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2899%2900003-3

Tamoxifen therapy in unresectable adenocarcinoma of the pancreas and the papilla of Vater

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2899%2900003-3

Clinical trial of tamoxifen in patients with irresectable pancreatic adenocarcinoma. The Yorkshire Gastrointestinal Tumour Group.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2899%2900003-3

Neoadjuvant therapy for unresectable pancreatic adenocarcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2899%2900003-3

Experimental pancreatic cancer in the rat treated by photodynamic therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2899%2900003-3

Factors influencing survival after pancreaticoduodenectomy for pancreatic cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2899%2900003-3

Prognostic factors for survival after pancreaticoduodenectomy for patients with carcinoma of the pancreatic head region

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2899%2900003-3

A prospective randomized trial of total parenteral nutrition after major pancreatic resection for malignancy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9610%2899%2900003-3

10.1016/S0002-9610(99)00003-3

7 January 2021

Identifiers

DOI

1 reference

28 July 2017

1 reference

PubMed ID

10219866